The CDIATM Tramadol Colloidal Gold Test Cassette (Urine) is a lateral flow chromatographic immunoassay for the detection of tramadol and its metabolites in human urine.
Tramadol antigen is coated on the test region of the nitrocellulose membrane of the strips, and tramadol antibody is labeled with colloid gold. During a test, the colloid gold labeled antibody coated in the strip move forward along the membrane, and a red line will show up when the antibody gathers with the antigen in the test line; if tramadol in the sample is over the detection limit, line T is blank; on the other wise, if tramadol in the sample is less than the detection limit, line T is red.
Tramadol is a centrally acting opioid analgesic, used in treating moderate to severe pain. Tramadol possesses weak agonist actions at the μ-opioid receptor, releases serotonin, and inhibits the reuptake of norepinephrine. Tramadol undergoes hepatic metabolism, being O-and N- demethylated to five different metabolites. Of these, O-desmethyltramadol is the most significant. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites, the remainder is excreted either as unidentified or an unextractable metabolites. The CDIATM Tramadol Colloidal Gold Test Cassette (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of tramadol in urine. The CDIATM Tramadol Colloidal Gold Test Cassette (Urine) yields a positive result when the tramadol in urine exceeds 200 ng/mL.